Report Overview

The Australian Melanoma drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Australia has one of thehighest rates of melanoma in the world, andmelanomais often referredto as 'Australia's national cancer'.Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. Melanoma is the deadliest form of skin cancer. It is estimated 1300 people will die from melanoma in Australia. Melanoma is the most common cancer affecting 15 to 39-year-old Australians. Melanoma is the third most common cancer in Australian men, after prostate and colorectal cancer Melanoma is the third most common cancer in Australian women, after breast and colorectal cancer.



Market Drivers

The rising prevalence rate of Melanoma is a major driver for the Melanoma market. This is mainly because an increase in the prevalence and incidence rate of Melanoma cases propels the need for drugs that enable efficient and fast treatment of the disease. Increasing pollution due to rapid industrialization and Increased Intensity of UV Radiation from the Sun are some of the reasons for the increasing prevalence of Melanoma. Hence all these factors have been driving the growth of the market. In 2017-18, net overseas migration was 236,700 and the natural increase was 153,800. In total, Australia's population grew by 390,500, or 1.6 percent. The ozone layer over Australia is particularly thin, and this protective layer is believed to have depleted by approximately 5-9% since the 1960s. That means significantly higher rates of UV radiation for Aussies who are out in the sun.